CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that the company and its academic collaborators will present clinical and preclinical data on several soluble guanylate cyclase (sGC) stimulators from Ironwood’s vascular and fibrotic disease platform at multiple upcoming scientific conferences. Currently, two of Ironwood’s investigational sGC stimulators, IW-1973 and IW-1701, are in Phase I studies, with multiple Phase II studies expected to initiate this year.
